Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The nicotinic receptor genes.

S Heinemann1, J Boulter, J Connolly

  • 1Molecular Neurobiology Laboratory, Salk Institute, San Diego, California.

Clinical Neuropharmacology
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Healthy environments for athleTes (HEAT): environmental conditions along a 90 km ultra-marathon event, South Africa.

International journal of biometeorology·2024
Same author

Considering community care in public health responses: A national study regarding palliative care during a prolonged coronavirus disease 2019 lockdown.

Australian and New Zealand journal of public health·2023
Same author

Complications with hot, cold and altitude environments in disaster management.

BMJ military health·2022
Same author

Proton beam radiotherapy for choroidal and ciliary body melanoma in the UK-national audit of referral patterns of 1084 cases.

Eye (London, England)·2022
Same author

An image-based eyelid lesion management service-evaluation of a pilot.

Eye (London, England)·2021
Same author

Skeletal deterioration in COL2A1-related spondyloepiphyseal dysplasia occurs prior to osteoarthritis.

Osteoarthritis and cartilage·2020
Same journal

Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.

Clinical neuropharmacology·2026
Same journal

Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.

Clinical neuropharmacology·2026
Same journal

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study.

Clinical neuropharmacology·2026
Same journal

A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.

Clinical neuropharmacology·2026
Same journal

Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.

Clinical neuropharmacology·2026
Same journal

Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.

Clinical neuropharmacology·2026
See all related articles

Alzheimer's disease (AD) research suggests altered nicotine binding sites. Investigating nicotinic acetylcholine receptor genes may lead to new treatments targeting AD progression.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • The exact causes of Alzheimer's disease (AD) remain unknown.
  • Alterations in high- to low-affinity nicotine binding sites are observed in AD patients.
  • Seven genes encoding nicotinic receptors in the brain have been identified.

Purpose of the Study:

  • To review the molecular genetic identification of nicotinic acetylcholine receptor (nAChR) subtypes.
  • To discuss methods for characterizing nAChR expression and function.
  • To explore the potential for developing targeted nAChR therapies for AD.

Main Methods:

  • Molecular genetic approaches to identify nAChR genes.
  • In situ hybridization to map mRNA expression of nAChR subtypes.

Related Experiment Videos

  • Patch clamp technique to analyze biophysical properties of nAChRs.

    • Main Results:

    • A family of genes coding for nAChR subtypes has been uncovered.
    • The distribution of mRNA for each receptor subtype has been determined.
    • The biophysical properties of expressed nAChR subtypes have been characterized.

    Conclusions:

    • Understanding nAChR gene promoters and receptor properties is crucial.
    • Development of specific nAChR subtype drugs could treat AD symptoms.
    • Targeting nAChRs may offer a strategy to slow Alzheimer's disease progression.